BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 16821585)

  • 1. Glucuronidation of SN-38 and NU/ICRF 505 in human colon cancer and adjacent normal colon.
    Cummings J; Ethell BT; Jardine L; Burchell B
    Anticancer Res; 2006; 26(3B):2189-96. PubMed ID: 16821585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives.
    Cummings J; Ethell BT; Jardine L; Boyd G; Macpherson JS; Burchell B; Smyth JF; Jodrell DI
    Cancer Res; 2003 Dec; 63(23):8443-50. PubMed ID: 14679008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins.
    Cummings J; Zelcer N; Allen JD; Yao D; Boyd G; Maliepaard M; Friedberg TH; Smyth JF; Jodrell DI
    Biochem Pharmacol; 2004 Jan; 67(1):31-9. PubMed ID: 14667926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation.
    Cummings J; Boyd G; Ethell BT; Macpherson JS; Burchell B; Smyth JF; Jodrell DI
    Biochem Pharmacol; 2002 Feb; 63(4):607-13. PubMed ID: 11992628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. UGT1A10 is responsible for SN-38 glucuronidation and its expression in human lung cancers.
    Oguri T; Takahashi T; Miyazaki M; Isobe T; Kohno N; Mackenzie PI; Fujiwara Y
    Anticancer Res; 2004; 24(5A):2893-6. PubMed ID: 15517893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Copper-transporting P-type ATPase, ATP7A, confers multidrug resistance and its expression is related to resistance to SN-38 in clinical colon cancer.
    Owatari S; Akune S; Komatsu M; Ikeda R; Firth SD; Che XF; Yamamoto M; Tsujikawa K; Kitazono M; Ishizawa T; Takeuchi T; Aikou T; Mercer JF; Akiyama S; Furukawa T
    Cancer Res; 2007 May; 67(10):4860-8. PubMed ID: 17510416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the major metabolite of the novel topoisomerase I inhibitor NU/ICRF 505.
    Cummings J; Meikle I; Macpherson JS; Smyth JF
    Anticancer Drug Des; 1996 Jul; 11(5):367-82. PubMed ID: 8765530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.
    Iyer L; King CD; Whitington PF; Green MD; Roy SK; Tephly TR; Coffman BL; Ratain MJ
    J Clin Invest; 1998 Feb; 101(4):847-54. PubMed ID: 9466980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues.
    Guichard S; Terret C; Hennebelle I; Lochon I; Chevreau P; Frétigny E; Selves J; Chatelut E; Bugat R; Canal P
    Br J Cancer; 1999 May; 80(3-4):364-70. PubMed ID: 10408839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The contribution of intestinal UDP-glucuronosyltransferases in modulating 7-ethyl-10-hydroxy-camptothecin (SN-38)-induced gastrointestinal toxicity in rats.
    Tallman MN; Miles KK; Kessler FK; Nielsen JN; Tian X; Ritter JK; Smith PC
    J Pharmacol Exp Ther; 2007 Jan; 320(1):29-37. PubMed ID: 17003228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential rates of glucuronidation for 7-ethyl-10-hydroxy-camptothecin (SN-38) lactone and carboxylate in human and rat microsomes and recombinant UDP-glucuronosyltransferase isoforms.
    Tallman MN; Ritter JK; Smith PC
    Drug Metab Dispos; 2005 Jul; 33(7):977-83. PubMed ID: 15833930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucuronidation of OTS167 in Humans Is Catalyzed by UDP-Glucuronosyltransferases UGT1A1, UGT1A3, UGT1A8, and UGT1A10.
    Ramírez J; Mirkov S; House LK; Ratain MJ
    Drug Metab Dispos; 2015 Jul; 43(7):928-35. PubMed ID: 25870101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics.
    Wen Z; Tallman MN; Ali SY; Smith PC
    Drug Metab Dispos; 2007 Mar; 35(3):371-80. PubMed ID: 17151191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of the novel topoisomerase I inhibitor NU/ICRF 505 and its major metabolite in plasma, tissue and tumour by high-performance liquid chromatography.
    Cummings J; Meikle I; Macpherson JS; Smyth JF
    J Chromatogr B Biomed Appl; 1996 Oct; 685(1):159-64. PubMed ID: 8930764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticancer effect of SN-38 on colon cancer cell lines with different metastatic potential.
    Wallin A; Svanvik J; Holmlund B; Ferreud L; Sun XF
    Oncol Rep; 2008 Jun; 19(6):1493-8. PubMed ID: 18497955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of apoptosis in human cancer cell lines by the novel anthracenyl-amino acid topoisomerase I inhibitor NU/ICRF 505.
    Meikle I; Cummings J; Macpherson JS; Smyth JF
    Br J Cancer; 1996 Aug; 74(3):374-9. PubMed ID: 8695351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models.
    Zamboni WC; Stewart CF; Cheshire PJ; Richmond LB; Hanna SK; Luo X; Poquette C; McGovren JP; Houghton JA; Houghton PJ
    Clin Cancer Res; 1998 Mar; 4(3):743-53. PubMed ID: 9533544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prominent but reverse stereoselectivity in propranolol glucuronidation by human UDP-glucuronosyltransferases 1A9 and 1A10.
    Sten T; Qvisen S; Uutela P; Luukkanen L; Kostiainen R; Finel M
    Drug Metab Dispos; 2006 Sep; 34(9):1488-94. PubMed ID: 16763014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus.
    Ciotti M; Basu N; Brangi M; Owens IS
    Biochem Biophys Res Commun; 1999 Jun; 260(1):199-202. PubMed ID: 10381366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Irinotecan inactivation is modulated by epigenetic silencing of UGT1A1 in colon cancer.
    Gagnon JF; Bernard O; Villeneuve L; Têtu B; Guillemette C
    Clin Cancer Res; 2006 Mar; 12(6):1850-8. PubMed ID: 16551870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.